{"@id":"https://bioecon.ru/technology/resistance-breaking-oncology-platform/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/resistance-breaking-oncology-platform/","json":"https://cn.bioecon.ru/api/v1/technology/resistance-breaking-oncology-platform/index.json"},"id":"resistance-breaking-oncology-platform","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/isomorphic-labs/","https://bioecon.ru/companies/micropep-technologies/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/genscript-probio-genscript/","https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/gilead-sciences/","https://bioecon.ru/companies/string-bio/"]},"maturity":7,"name":"克服肿瘤获得性耐药的新一代靶向药物研发平台","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"循环肿瘤DNA耐药突变克隆演化监测"},{"n":2,"title":"非ATP竞争性空间变构抑制剂设计"},{"n":3,"title":"全基因组CRISPR合成致死旁路筛选"},{"n":4,"title":"临床耐药复发患者来源PDX/PDO模型验证"}],"summary":"通过高灵敏度循环肿瘤DNA（ctDNA）动态追踪结合基于空间结构的变构药物化学，前瞻性预测耐药突变演化轨迹，开发针对看门基因突变及旁路旁路激活的新一代抗耐药小分子靶向药物。","url":"/technology/resistance-breaking-oncology-platform/","verified":"2026-11-22"}